Abstract B017: Understanding the impact of transporter heterogeneity on the efficacy of PARP inhibitors

Carmen Ramirez Moncayo,Guanying Zhang,Alexis Barr,Vincen Wu,Christina Fotopoulou,Paula Cunnea,Zoe Hall,Louise Fets
DOI: https://doi.org/10.1158/1538-7445.ovarian23-b017
IF: 11.2
2024-03-05
Cancer Research
Abstract:While PARP inhibitors have undoubtedly enhanced the prognosis of high-grade serous ovarian cancer (HGSOC) patients, variability in response and acquired drug resistance remain persistent hurdles undermining these drugs' effectiveness. One of the multiple mechanisms of resistance ascribed to PARP inhibitors involves transporter-dependent detoxification, facilitated by the overexpression of the multidrug-resistant protein MDR1, which couples ATP hydrolysis to drug efflux. Conversely, the Solute Carrier (SLC) family of transporters plays a role in the cellular uptake of multiple therapeutic compounds, whereby the presence and abundance of the relevant transporter at the plasma membrane may dictate intracellular concentration of the drug, with subsequent clinical implications. Despite these findings, our understanding of PARP inhibitor drug uptake mechanisms, and how heterogeneity of transporter expression limits drug efficacy, remains limited. To better understand this, we employed a combination of cell-based high-content microscopy assays and multimodal molecular tissue imaging techniques to investigate the heterogeneity in response to PARP inhibitors and their relationship to drug distribution. Mass spectrometry imaging of human HGSOC tumor explants demonstrated intra-tumor heterogeneity in PARP inhibitor uptake within clinical samples. Even at the single cell level, heterogeneity in PARP inhibitor uptake was observed, and this was seen to correlate with levels of DNA damage, suggesting that differences in drug distribution may limit PARP inhibitor response and contribute to acquired drug resistance. Taken together, this data suggests that diverse transporter signatures in cancer could contribute to patient-to-patient variability in PARP inhibitor response. The identification of the molecular determinants of the heterogeneity hitherto described might contribute towards a better understanding of drug sensitivity and acquired drug resistance, with the idea of improving patient stratification in the context of personalized medicine. Citation Format: Carmen Ramirez Moncayo, Guanying Zhang, Alexis Barr, Vincen Wu, Christina Fotopoulou, Paula Cunnea, Zoe Hall, Louise Fets. Understanding the impact of transporter heterogeneity on the efficacy of PARP inhibitors [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2) nr B017.
oncology
What problem does this paper attempt to address?